Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Loss of skeletal muscle mass in cancer cachexia is recognized as a predictor of mortality. This study aimed to characterize the changes in the muscle secretome associated with cancer cachexia to gain a better understanding of the mechanisms involved and to identify secreted proteins which may reflect this wasting process. The changes in the muscle proteome of the C26 model were investigated by label-free proteomic analysis followed by a bioinformatic analysis in order to identify potentially secreted proteins. Multiple reaction monitoring and Western blotting were used to verify the presence of candidate proteins in the circulation. Our results revealed a marked increased muscular production of several acute phase reactants (APR: Haptoglobin, Serine protease inhibitor A3N, Complement C3, Serum amyloid A-1 protein) which are released in the circulation during C26 cancer cachexia. This was confirmed in other models of cancer cachexia as well as in cancer patients. Glucocorticoids and proinflammatory cytokines are responsible for an increased production of APR by muscle cells. Finally, their muscular expressions are strongly positively correlated with body weight loss as well as the muscular induction of atrogens. Our study demonstrates therefore a marked increased production of APR by the muscle in cancer cachexia.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693727PMC
http://dx.doi.org/10.3390/cancers12113221DOI Listing

Publication Analysis

Top Keywords

cancer cachexia
24
marked increased
12
increased production
12
production acute
8
acute phase
8
phase reactants
8
skeletal muscle
8
muscle cancer
8
changes muscle
8
identify secreted
8

Similar Publications

Cancer cachexia is a highly debilitating clinical syndrome of involuntary body mass loss featuring profound muscle wasting leading to high mortality. Notably, cardiac wasting is prominent in cancer patients and cancer survivors. Cachexia studies present significant challenges due to the absence of human models and mainly short-term animal studies.

View Article and Find Full Text PDF

Background: Combination therapy with enfortumab vedotin plus pembrolizumab (EV+P) is now the preferred first-line (1L) therapy for advanced urothelial carcinoma (aUC), but prognostic indicators for patients on 1L EV+P have not yet been described.

Patients And Methods: We conducted a retrospective cohort study of patients receiving 1L EV+P for aUC. We analyzed deidentified electronic health record data from the Flatiron Health database to identify adults with aUC who initiated EV+P between April 3, 2023 and December 31, 2024.

View Article and Find Full Text PDF

Purpose: There are no methods for assessing the need for multimodal care in cancer cachexia. We examined nine components in evaluating needs among advanced cancer patients.

Methods: This was a self-administered survey.

View Article and Find Full Text PDF

Eggs play an important role in skeletal muscle development, but their active components are unknown. The aim of this study was to investigate the effect of yolk extract-derived vitellogenin 2 on dexamethasone (DEX)- and cancer cachexia (CC)-induced skeletal muscle atrophy. We used iTRAQ to detect the changes in protein expression between fertilized egg yolk extract (FEYE) and unfertilized egg yolk extract (UEYE).

View Article and Find Full Text PDF